AU2018321950A1 - Compositions and methods for treating cancer - Google Patents
Compositions and methods for treating cancer Download PDFInfo
- Publication number
- AU2018321950A1 AU2018321950A1 AU2018321950A AU2018321950A AU2018321950A1 AU 2018321950 A1 AU2018321950 A1 AU 2018321950A1 AU 2018321950 A AU2018321950 A AU 2018321950A AU 2018321950 A AU2018321950 A AU 2018321950A AU 2018321950 A1 AU2018321950 A1 AU 2018321950A1
- Authority
- AU
- Australia
- Prior art keywords
- subject
- onecut2
- agent
- day
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 C[*-]C(NCCC(NCCc(c(O)c1O)ccc1O)=O)=O Chemical compound C[*-]C(NCCC(NCCc(c(O)c1O)ccc1O)=O)=O 0.000 description 30
- MYUPFPPGGOZEAF-QMMMGPOBSA-N N[C@@H](CO)c1ncc(-c2ccccc2O)[nH]1 Chemical compound N[C@@H](CO)c1ncc(-c2ccccc2O)[nH]1 MYUPFPPGGOZEAF-QMMMGPOBSA-N 0.000 description 4
- NLSKEGYQPIUTJY-UHFFFAOYSA-N Cc(c(O)ccc1CCNC(N(CCCC2)C2C(N)=O)=O)c1O Chemical compound Cc(c(O)ccc1CCNC(N(CCCC2)C2C(N)=O)=O)c1O NLSKEGYQPIUTJY-UHFFFAOYSA-N 0.000 description 2
- VTVXLYAWESBRLJ-UHFFFAOYSA-N NC(C(CCCC1)N1C(NCCc(ccc(O)c1O)c1O)=O)=O Chemical compound NC(C(CCCC1)N1C(NCCc(ccc(O)c1O)c1O)=O)=O VTVXLYAWESBRLJ-UHFFFAOYSA-N 0.000 description 2
- MQIJUASIGZRXAO-JTQLQIEISA-N N[C@@H](CO)C(NC(C1)CN1C(c1ccccc1O)=O)=O Chemical compound N[C@@H](CO)C(NC(C1)CN1C(c1ccccc1O)=O)=O MQIJUASIGZRXAO-JTQLQIEISA-N 0.000 description 2
- YALLBXSBAHHDTG-UHFFFAOYSA-N Oc(ccc(CCNC(C(CC1)CNC1=O)=O)c1O)c1O Chemical compound Oc(ccc(CCNC(C(CC1)CNC1=O)=O)c1O)c1O YALLBXSBAHHDTG-UHFFFAOYSA-N 0.000 description 2
- UBDWBMGZTDDXCP-UHFFFAOYSA-N C=C(CN)N(CCC1)C1C(N)=O Chemical compound C=C(CN)N(CCC1)C1C(N)=O UBDWBMGZTDDXCP-UHFFFAOYSA-N 0.000 description 1
- CEPJJTIDOCHYPT-UHFFFAOYSA-N CC(C(CO)=N)=O Chemical compound CC(C(CO)=N)=O CEPJJTIDOCHYPT-UHFFFAOYSA-N 0.000 description 1
- NSRPFJGOCZUUHE-UHFFFAOYSA-N CC(CC1)CNC1=O Chemical compound CC(CC1)CNC1=O NSRPFJGOCZUUHE-UHFFFAOYSA-N 0.000 description 1
- ABGHSVNLDKGSQK-UHFFFAOYSA-N CC(NCCC(NCCc(c(O)c1O)ccc1O)=O)=O Chemical compound CC(NCCC(NCCc(c(O)c1O)ccc1O)=O)=O ABGHSVNLDKGSQK-UHFFFAOYSA-N 0.000 description 1
- HGPVTSXCIFGEST-BYPYZUCNSA-N CC([C@H](CO)N)=O Chemical compound CC([C@H](CO)N)=O HGPVTSXCIFGEST-BYPYZUCNSA-N 0.000 description 1
- KQAQHJVEWISMLJ-WMEQCIOUSA-N CC1C=CC=CC1(C)C(N(C1)CC1NC([C@H](CO)N)=O)=C Chemical compound CC1C=CC=CC1(C)C(N(C1)CC1NC([C@H](CO)N)=O)=C KQAQHJVEWISMLJ-WMEQCIOUSA-N 0.000 description 1
- HILXVWLAWXBQMU-UHFFFAOYSA-N CCC(N(CCC1)C1C(OC)=O)=O Chemical compound CCC(N(CCC1)C1C(OC)=O)=O HILXVWLAWXBQMU-UHFFFAOYSA-N 0.000 description 1
- DJDHQJFHXLBJNF-UHFFFAOYSA-N CCCc(c(O)c1)ccc1O Chemical compound CCCc(c(O)c1)ccc1O DJDHQJFHXLBJNF-UHFFFAOYSA-N 0.000 description 1
- OOKSJQADSGPLLX-UHFFFAOYSA-N CN(C)C(C(CCCC1)N1C(CCCCc(c(O)c1O)ccc1O)=O)=O Chemical compound CN(C)C(C(CCCC1)N1C(CCCCc(c(O)c1O)ccc1O)=O)=O OOKSJQADSGPLLX-UHFFFAOYSA-N 0.000 description 1
- GJGVBBJAMUSFJE-LBPRGKRZSA-N CN(C)[C@@H](CO)c1ncc(-c2ccccc2O)[N]1(C)C Chemical compound CN(C)[C@@H](CO)c1ncc(-c2ccccc2O)[N]1(C)C GJGVBBJAMUSFJE-LBPRGKRZSA-N 0.000 description 1
- NBFVMBGIPAJCJQ-UHFFFAOYSA-N CN(CCCC1)C1C(N)=O Chemical compound CN(CCCC1)C1C(N)=O NBFVMBGIPAJCJQ-UHFFFAOYSA-N 0.000 description 1
- PSTKXCFZIPHQIT-UHFFFAOYSA-N CNC(C(CCCC1)N1C([N-](C)CCc(c(O)c1O)ccc1O)=O)=O Chemical compound CNC(C(CCCC1)N1C([N-](C)CCc(c(O)c1O)ccc1O)=O)=O PSTKXCFZIPHQIT-UHFFFAOYSA-N 0.000 description 1
- QXWSSTJXRBRPAJ-JTQLQIEISA-N CN[C@@H](CO)c1ncc(-c(cccc2)c2O)[n]1C Chemical compound CN[C@@H](CO)c1ncc(-c(cccc2)c2O)[n]1C QXWSSTJXRBRPAJ-JTQLQIEISA-N 0.000 description 1
- BMMDDMDYYMJQJH-VIFPVBQESA-N Cc(c(O)c(CCNC([C@H](CO)N)=O)cc1)c1O Chemical compound Cc(c(O)c(CCNC([C@H](CO)N)=O)cc1)c1O BMMDDMDYYMJQJH-VIFPVBQESA-N 0.000 description 1
- PKSMOJNQRQZSOD-AWEZNQCLSA-N Cc1ccccc1C(N(C1)CC1NC([C@H](CO)N)=O)=C Chemical compound Cc1ccccc1C(N(C1)CC1NC([C@H](CO)N)=O)=C PKSMOJNQRQZSOD-AWEZNQCLSA-N 0.000 description 1
- NNHCNBPRBODZOP-UHFFFAOYSA-N NC(C(CCCC1)N1C(NCCc(ccc(OCc1ccccc1)c1OCc2ccccc2)c1OCc1ccccc1)=O)=O Chemical compound NC(C(CCCC1)N1C(NCCc(ccc(OCc1ccccc1)c1OCc2ccccc2)c1OCc1ccccc1)=O)=O NNHCNBPRBODZOP-UHFFFAOYSA-N 0.000 description 1
- OVYSAAFVKLSMBM-PKPIPKONSA-N N[C@@H](CO)C(NCC(N(CCC1)C1C(N)=O)=O)=O Chemical compound N[C@@H](CO)C(NCC(N(CCC1)C1C(N)=O)=O)=O OVYSAAFVKLSMBM-PKPIPKONSA-N 0.000 description 1
- YXSOYDSVRFACNB-VIFPVBQESA-N N[C@@H](CO)C(NCCc1n[nH]c2ccccc12)=O Chemical compound N[C@@H](CO)C(NCCc1n[nH]c2ccccc12)=O YXSOYDSVRFACNB-VIFPVBQESA-N 0.000 description 1
- XUSDHLVIRLAMEH-UHFFFAOYSA-N Oc(ccc(CC(NCC(NO)=O)=O)c1O)c1O Chemical compound Oc(ccc(CC(NCC(NO)=O)=O)c1O)c1O XUSDHLVIRLAMEH-UHFFFAOYSA-N 0.000 description 1
- CVIRHNYTKYHNEI-UHFFFAOYSA-L [NH-]C(C(CCCC1)N1C([N-]CCc(ccc(O)c1O)c1O)=O)=O Chemical compound [NH-]C(C(CCCC1)N1C([N-]CCc(ccc(O)c1O)c1O)=O)=O CVIRHNYTKYHNEI-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762548879P | 2017-08-22 | 2017-08-22 | |
| US62/548,879 | 2017-08-22 | ||
| PCT/US2018/047569 WO2019040647A1 (en) | 2017-08-22 | 2018-08-22 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2018321950A1 true AU2018321950A1 (en) | 2020-03-19 |
Family
ID=65440144
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2018321950A Abandoned AU2018321950A1 (en) | 2017-08-22 | 2018-08-22 | Compositions and methods for treating cancer |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11529338B2 (enExample) |
| EP (1) | EP3672582A4 (enExample) |
| JP (1) | JP7293194B2 (enExample) |
| CN (1) | CN111182894A (enExample) |
| AU (1) | AU2018321950A1 (enExample) |
| CA (1) | CA3073669A1 (enExample) |
| IL (1) | IL272782A (enExample) |
| WO (1) | WO2019040647A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017213897A1 (en) | 2016-06-09 | 2017-12-14 | Cedars-Sinai Medical Center | Compositions and methods for treating cancer |
| AU2020363360A1 (en) * | 2019-10-07 | 2022-05-05 | D.E Shaw Research, Llc | Arylmethylene heterocyclic compounds as Kv1.3 potassium shaker channel blockers |
| PL447378A1 (pl) * | 2023-12-29 | 2025-06-30 | Uniwersytet Medyczny W Lublinie | Zastosowanie lepidylin w leczeniu nowotworu układu nerwowego. |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3270960A (en) | 1964-09-11 | 1966-09-06 | Sperry Rand Corp | Fluid sensor |
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| CA1294215C (en) | 1986-10-27 | 1992-01-14 | Ze'ev Shaked | Pharmaceutical compositions of recombinant beta-interferon and formulation processes |
| CA1292686C (en) | 1986-10-27 | 1991-12-03 | Ze'ev Shaked | Pharmaceutical compositions of recombinant interleukin-2 and formulation process |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US6048877A (en) * | 1997-02-21 | 2000-04-11 | Bristol-Myers Squibb Company | Tetralone derivatives as antiarrhythmic agents |
| US6218367B1 (en) | 1998-09-15 | 2001-04-17 | Organomed Corporation | Paclitaxel-carbohydrate conjugates: design, synthesis and biological evaluations |
| KR20060031809A (ko) | 2003-06-09 | 2006-04-13 | 더 리젠츠 오브 더 유니버시티 오브 미시간 | 암 치료 및 진단용 조성물 및 방법 |
| US7892740B2 (en) | 2006-01-19 | 2011-02-22 | The University Of Chicago | Prognosis and therapy predictive markers and methods of use |
| DK2245199T3 (da) | 2008-02-01 | 2014-02-03 | Gen Hospital Corp | Anvendelse af mikrovesikler i diagnosticering, prognosticering og behandling af medicinske sygdomme og tilstande |
| US20140056807A1 (en) | 2012-08-23 | 2014-02-27 | Cedars-Sinai Medical Center | Large oncosomes in human tumors and in circulation in patients with cancer |
| WO2014164730A2 (en) | 2013-03-12 | 2014-10-09 | The Board Of Trustees Of The Leland Stanford Junior University | Modulation of cellular dna repair activity to intercept malignancy |
| EP2986326B1 (en) | 2013-04-15 | 2018-09-05 | Cedars-Sinai Medical Center | Methods for detecting cancer metastasis |
| US20170051149A1 (en) | 2014-04-29 | 2017-02-23 | Ecole Normale Superieure De Lyon | Azoaryls as reversibly modulatable tubulin inhibitors |
| US20170144965A1 (en) | 2014-06-05 | 2017-05-25 | The University Of Kansas | Marmelin analogs and methods of use in cancer treatment |
| WO2015197909A1 (en) | 2014-06-27 | 2015-12-30 | Fermion Oy | Process for the preparation of a crystalline polymorph of 2-amino-3-hydroxy-n'-(2,3,4-trihydroxybenzyl)propanehydrazide (benserazide) hydrochloride |
| CA2996426A1 (en) | 2015-10-05 | 2017-04-13 | Cedars-Sinai Medical Center | Method of classifying and diagnosing cancer |
| WO2017213897A1 (en) * | 2016-06-09 | 2017-12-14 | Cedars-Sinai Medical Center | Compositions and methods for treating cancer |
-
2018
- 2018-08-22 EP EP18848878.7A patent/EP3672582A4/en active Pending
- 2018-08-22 AU AU2018321950A patent/AU2018321950A1/en not_active Abandoned
- 2018-08-22 WO PCT/US2018/047569 patent/WO2019040647A1/en not_active Ceased
- 2018-08-22 US US16/640,902 patent/US11529338B2/en active Active
- 2018-08-22 CN CN201880061797.2A patent/CN111182894A/zh active Pending
- 2018-08-22 CA CA3073669A patent/CA3073669A1/en active Pending
- 2018-08-22 JP JP2020510543A patent/JP7293194B2/ja active Active
-
2020
- 2020-02-19 IL IL272782A patent/IL272782A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2020531495A (ja) | 2020-11-05 |
| CA3073669A1 (en) | 2019-02-28 |
| US20200188373A1 (en) | 2020-06-18 |
| JP7293194B2 (ja) | 2023-06-19 |
| EP3672582A4 (en) | 2021-05-05 |
| EP3672582A1 (en) | 2020-07-01 |
| IL272782A (en) | 2020-04-30 |
| WO2019040647A1 (en) | 2019-02-28 |
| CN111182894A (zh) | 2020-05-19 |
| US11529338B2 (en) | 2022-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12421185B2 (en) | Compositions and methods for treating cancer | |
| US10793565B2 (en) | Heterocyclic compounds as immunomodulators | |
| RU2701193C2 (ru) | Арилхиназолины | |
| US20200407357A1 (en) | Heterocyclic compounds as immunomodulators | |
| CN109516999B (zh) | 用作蛋白质激酶调节剂的化合物及其应用 | |
| IL229988A (en) | 4,4,4-trifluoro-n-[(1s)-2[[(7s)-5-(2-hydroxyethyl)-6-oxo-7h-pyrido[2,3-d] [3]benzazepine-7-yl]amino]-1-methyl-2-oxo-ethyl]butanamide, its use in the manufacture of medicaments for treating cancer and crystalline hydrates thereof | |
| CN115368381A (zh) | 杂环类抑制剂的制备及其应用 | |
| US11529338B2 (en) | Compositions and methods for treating cancer | |
| JP7611934B2 (ja) | ピラゾロピリダジノン化合物、その医薬組成物及びその用途 | |
| CN1893944B (zh) | 具有抗增殖活性的3-氰基喹啉衍生物 | |
| US20070244110A1 (en) | Treatment of prostate cancer, melanoma or hepatic cancer | |
| WO2022242725A1 (zh) | 一类新型蛋白降解剂及其应用 | |
| CN114436976A (zh) | 一种新型喹唑啉类衍生物及其制备和应用 | |
| JP2025535017A (ja) | Ｉａｐの阻害剤として有用な化合物及び組成物 | |
| CN112876463A (zh) | 一种制备pd-l1拮抗剂的中间体及其制备方法 | |
| CN103936742B (zh) | 含嘌呤基的新型pi3k抑制剂及其制备方法和应用 | |
| CN110251518A (zh) | 1,2,4-三氮唑类杂环化合物在制备预防或治疗与中枢系统相关疾病药物中的应用 | |
| CN115427407A (zh) | 一种新型n-杂环bet溴结构域抑制剂、其制备方法及医药用途 | |
| CN103214467B (zh) | 5-[[4-[(2,3-二甲基-2h-吲唑-6-基)甲氨基]-2嘧啶基]氨基]-2-甲基-苯磺酰胺衍生物及其制备方法与应用 | |
| WO2023150206A2 (en) | Red-shifted fluorophores and methods of using the same | |
| CN115215883A (zh) | Usp7抑制剂 | |
| CN115304598B (zh) | 一种杂环类化合物及其制备方法和用途 | |
| CN112979663B (zh) | 一种具有神经康复作用的含氮化合物及其应用 | |
| CN115677601B (zh) | 一种具有抗肿瘤活性的化合物及其用途 | |
| WO2025221986A1 (en) | Targeted camptothecin derivatives for cancer treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1 | Application lapsed section 142(2)(a) - no request for examination in relevant period |